Drug targeting systems for cancer chemotherapy

Bibliography

• CUMMINGS J, SYMTH JF: Pharmaceutical Aspects of Cancer Chemotherapy. Florence AT, Sable EG (Eds.), Butterworth-Heineman, Oxford (1993):27–53.
   Google Scholar
• UNGER C: Current concepts of treatment in medicaloncology: new anticancer drugs. J. Cancer Res. Clin. On-col. (1996) 122:189–198.
   PubMed Web of Science ®Google Scholar
• ROTHA JA, CRISTIANO RJ: Gene therapy for cancer:what have we done and where are we going ? J. Natl. Cancer Inst. (1997) 89:21–39.
   Google Scholar
• •A thorough review of the direction gene therapy is taking in the area of cancer.
   Google Scholar
• CHO MJ, JULIANO R: Macromolecular versus small molecule therapeutics: drug discovery, developments and clinical considerations. Trends Biotech. (1996) 14:153–158.
   PubMed Web of Science ®Google Scholar
• LEON JA, GOLDSTEIN NI, FISHER PB: New approaches for the development and application of monoclonal antibodies for the diagnosis and therapy of human cancer. Pharm. Ther. (1994) 61:237–238.
   PubMed Web of Science ®Google Scholar
• VITETTA ES: Immunotoxins: magic bullets or mis-guided missiles? Trends Pharmacol. Sci. (1993) 14:148–154.
   Google Scholar
• ••Discusses in detail the limitations of using immunotoxinsand what are the future approaches for improving their delivery.
   Google Scholar
• BETTER M, WEICKMAN J: Engineering the bullet: anti-bodies and bacteria. Chemtech. (1993) May:14–20.
   Google Scholar
• WINTER G, HARRIS WJ: Humanized antibodies. Trends Pharmacol. ScL (1993) 14:139–142.
   PubMed Web of Science ®Google Scholar
• FORSSEN E: The design and development of Dauno Xome for solid tumour targeting in vivo. Advan. Drug Delivery Rev. (1997) 24:133–150.
   Web of Science ®Google Scholar
• ••Explains the sequence of events involved in the develop-ment of DaunoXome.
   Google Scholar
• FORSSEN EA, MALE'-BRUNE, ALDER-MOORE JP et al.: Flurescence imaging studies for the disposition of daunorubicin liposomes (daunoxome) within tumour tissue. Cancer Res. (1996) 56:2066–2075.
   Google Scholar
• ADLER-MOORE JP, PROFFITT RT: Development, charac-terization, efficacy and mode of action of AmBisome. J. Liposome Res. (1993) 3:429–450.
   Google Scholar
• TREAT J, GREENSPAN A, FORST D: Antitumour activity of liposome-encapsulated doxorubicin in advanced breast cancer: Phase II study. J. Nat. Cancer Inst. (1990) 21:1706–1710.
   Google Scholar
• PAPAHADJOPULOS D, ALLEN TM, GABIZON A et al: Steri-cally stabilized liposomes: improvements in pharma-cokinetics and antitumour therapeutic efficacy. Proc. Natl. Acad. Sci. (1991) 88:11460–11464.
   PubMed Web of Science ®Google Scholar
• STORM G, BLOIS L, STEERENBERG PA et al.: Liposome en-capsulation of doxorubicin: pharmaceutical and therapeutic effects. J. Cont. Rel. (1989) 9:215–229.
   Web of Science ®Google Scholar
• FORSEN EA, COULERT DM, PROFFIT T: Selective in vivo localization of daunorubicin small unilamellar vesi-cles in solid tumour. Cancer Res. (1992) 52:3255–3261.
   PubMed Web of Science ®Google Scholar
• LASIC DD: Doxorubicin in sterically stabilized lipo-somes. Nature (1996) 380: 561–562.
   PubMed Web of Science ®Google Scholar
• •Discusses the Doxil formulation.
   Google Scholar
• ALLEN TM: Long-circulating sterically stabilized 1 lipo- somes for targeted drug delivery. Trends Pharm. ScL (1994) 15:215–220.
   PubMed Web of Science ®Google Scholar
• FORSSE EA, COULTER D, PROFITT R: Selective in vivo lo-calization of daunorubicin small unilamellar vesicles in solid tumours. Cancer Res. (1992) 52:3255–3261.
   PubMed Web of Science ®Google Scholar
• KIRPOTIN D, PARK JW, HONG K et al.: Sterically stabi-lized anti-Her2 immunoliposomes: design and target-ing to human breast cancer cells in vitro. Biochemistry (1997) 36:66–75.
   PubMed Web of Science ®Google Scholar
• •A detail discussion of the role of immunoliposomes in can-cer treatment.
   Google Scholar
• HANSEN C, KAO G, MOASE E, ZALIPSKY S, ALLEN TM,: At- tachment of antibodies to sterically stabilized lipo-somes: evaluation, comparison and optimization of coupling process. Biochim. Biophys. Acta (1995) 1239:133–144.
   PubMed Web of Science ®Google Scholar
• •One of the earlier papers discussing the conjugation of monoclonal antibodies to liposomes.
   Google Scholar
• NEEDHAM D, MACINTOSH TJ, LASIC DD: Repulsive in- teractions and mechanical stability of polymer grafted lipid bilayer. Biochim. Biophysl. Acta (1992) 1108:40–48.
   PubMed Web of Science ®Google Scholar
• HUANG SK, MAYEW E, GILANI et al Pharmacokinetics and therapeutics of sterically stabilized liposomes in mice with C-26 colon carcinoma. Cancer Res. (1992) 52 6774–6781
   PubMed Web of Science ®Google Scholar
• AHMED I, LONGENECKER M, SAMUEL J, ALLEN T: Anti- body targeted delivery of doxorubicin in stealth lipo-somes can eradicate lung cancer in mice. Cancer Res. (1993) 53:1484–1488.
   PubMed Web of Science ®Google Scholar
• •A novel method of conjugation of liposomes to antibodies.
   Google Scholar
• SELA D, HUSAIN S, PEARSON J, LONGO D: Reversal of multidrug resistance in human colon cancer cells ex-pressing the human mdri gene by liposomes in combi-nation with monoclonal antibody or verapamil. J. Nat. Cancer Inst. (1995) 87:23–128.
   Google Scholar
• ALAIN T, ANATOLY D, RAHMAN A: Effect of Liposomes on P-glycoprotein function in multidrug resistant cells. Biochem. Biophys. Res. Comm. (1992) 187(2)1098–1105.
   Google Scholar
• OUDARD S, THIERRY A, JORGENSEN T, RAHMAN A: Sen- sitization of multidrug-resistant colon cancer cells to doxorubicin encapsulation liposomes. Cancer Chemo. Pharmacol. (1991) 28:259–265.
   PubMed Web of Science ®Google Scholar
• •A controversial paper about the role of liposomes in revers-ing drug-resistance.
   Google Scholar
• LEGENDRE J, SZOKA FC: Delivery of plasmid DNA into mammalian cell lines using pH sensitive liposomes: comparison with cationic liposomes. Pharm. Res. (1992) 9:1235–1242.
   PubMed Web of Science ®Google Scholar
• ZHOU X, HUANG L: DNA transfection mediated by lipo-some containing lipopolylysine: characterization and mechanism of action. Biochim. Biophys. Acta (1994) 1189:195–203.
   PubMed Web of Science ®Google Scholar
• JARNAGIN WR, DEBS RJ, WANG SS: Cationic lipid-mediated transfection of liver cells in primary culture. Nucleic Acids Res. (1992) 20:4205–4211.
   PubMed Web of Science ®Google Scholar
• FARHOOD K, HUANG L: Delivery of DNA, RNA and pro-teins by cationic liposomes. In: Handbook of Non-Medical Applications of Liposomes. Lasic DD (Ed.), Baren-holz (1996) 4:31–42.
   Google Scholar
• GOA X, HUANG L: A novel cationic liposome reagent for efficient transfection of mammalian cells. Biophys. Biochem. Res. Commun. (1991) 179:280–285.
   PubMed Web of Science ®Google Scholar
• LASIC DD, PODGORNIK R, STREY H, STUART M, FRE-DERIK P: DNA-cationic lipid complexes: structure and structure-activity relationships. J. Am. Chem. Soc. (1997) 119:832–833.
   Web of Science ®Google Scholar
• CAPLEN NJ, ALTON EWFW, MIDDLETON PG et al.: Lipo-some mediated CFTR gene transfer to the nasal epithe-1Mm of patients with cystic fibrosis. Nature Med. (1995) 1:39–46.
   PubMed Web of Science ®Google Scholar
• AKHTAR S, LEWIS KJ: Antisense oligodeoxynucleotidedelivery to cultured macrophages is improved by in-corporation into sustained release biodegradable polymer microspheres. Int. J. Pharmaceut. (1997) 151:57–67.
   Web of Science ®Google Scholar
• JULIANO RL AKHTAR S: Liposomes as a drug delivery system for antisense oligonucleotides. Antisense Search Dev. (1992) 2:165–171.
   PubMedGoogle Scholar
• •The role of cationic liposomes in delivering oligonucleotides.
   Google Scholar
• LEWIS KJ, IRWIN WJ, AKHTAR S: Biodegradable P(LA-GA) microspheres for the sustained delivery of an-tisense oligonucleotides. J. Drug Target. (In Press.)
   Google Scholar
• NARULA J, KHAW BA: One step forward with non-specifically-specific monoclonal antibodies. J. Nucl. Med. (1990) 31:1066–1068.
   PubMed Web of Science ®Google Scholar
• RANA TM, MEARES CF: N-terminal modification of im-munogloubin polypeptide chains tagged with isothio-cyanato chelates. Bioconjug. Chem. (1990) 120:290–296.
   Google Scholar
• CHENG FM, HENASEN EB, TAYLOR CR, EPSTEIN AL: Dif-fusion and binding of monoclonal antibody TNT-1 in multicellular tumor spheroids. J. Natl. Cancer Inst. (1991) 83 3:200–204.
   PubMed Web of Science ®Google Scholar
• LEWIS JP, DENARDO GI: Radioimmunotherapy of lym-phoma: a UC Davis experience. Hybridoma (1995) 14:115–120.
   PubMed Web of Science ®Google Scholar
• HU P, GLASKY MS, YUN A et al: A human mouse derived chimeric Lym-1 monoclonal antibody with specificity for human lymphomas expressed in a baculovirus sys-tem. Hum. Antibodies Hybridomas (1995) 6:57–67.
   PubMedGoogle Scholar
• DENARDO GI, LEWIS JP, DENARDO SJ, O'GRADY LF: Ef-fect of Lym-1 radioimmunoconjugate on refractory chronic lymphocytic leukemia. Cancer (1994) 73:1425–1432.
   PubMed Web of Science ®Google Scholar
• DENARDO GI, MAHE MA, DENARDO SJ, MACEY DJ, GROCH MW: Body and blood clearance and marrow ra-diation dose of 1i1I-Lym-1 in patients with B-cell mali-ganancies. Nucl. Med. Commun. (1993)14:587–595.
   PubMed Web of Science ®Google Scholar
• CEMERLIC D, DADEY B, HAN T, VAICKUS I. Cytokine in-fluence on killing of fresh chronic lymphocytic leuke-mia cells by human leukocytes. Blood (1991) 77:2707–2715.
   PubMed Web of Science ®Google Scholar
• LEBERTHON B, KHAWLI LA, ALAUDDIN M et al.: En-hanced tumour uptake of macromolecules induced by a novel vasoactive interleukin 2 immunoconjugate. Cancer Res. (1991) 51:2694–2698.
   PubMed Web of Science ®Google Scholar
• LIU C, LAMBERT JM, TEICHER BA, BLATTER WA, O'CON-NER R: Cure of multi-drug human B-cell lymphoma xe-nografts by combinations of anti-B4-bR blocked ricin and chemotherapeutic drugs. Blood (1996) 87:3892–3898.
   PubMed Web of Science ®Google Scholar
• •Development of the antiB4bR conjugate, which was later dropped from Phase III clinical trials.
   Google Scholar
• O'CONNOR R, LIU C, FERRIS CA: Anti-B4-bR blockedricin synergizes with doxorubicin and etoposide on multidrug resistant and drug sensitive tumors. Blood (1995) 86:4286–4294.
   PubMed Web of Science ®Google Scholar
• SHAH SA, LAMBERT JM, GOLMACHER VS et al.: Evalua-tion of the systemic toxicity and pharmacokinetics of the immunoconjugate anti-B4-blocked ricin in non-human primates. Delivered by multiple bolus injec-tions and by continuous infusion. Int. J. Immunopharm. (1993) 15:723–736.
   Google Scholar
• SINGH M, GRIFFIN T, SALIMI A, MICETICH RG, ATWAL H:Potentiation of ricin A immunotoxin by monoclonal antibody targeted monensin containing small unilamellar vesicles. Cancer Lett. (1994) 84:15–21.
   PubMed Web of Science ®Google Scholar
• FERDOUS A, STEMBRIDGE N, SINGH M: Monensin PLGApolymer particles as potentiator of ricin A immuno-toxin in vitro. J. Controlled Release (1998) 50:71.
   PubMed Web of Science ®Google Scholar
• GRIFFIN T, RYBAK M, RECHT L et al: Potentiation of anti-tumor immunotoxins by liposomal monensin. (1993) J. Nail Cancer Inst. 85(4):292–298.
   PubMed Web of Science ®Google Scholar
• FISHWILD DM, WU HM: Characterization of the in-creased cytotoxcity of gelonin anti-T cell immunocon-jugates compared with ricin A chain immunoconjugates with unique properties. Clin. Exp. Immunol. (1994) 97(0:10–18.
   PubMedGoogle Scholar
• BETTER M, BERNHARD SI, FISHWILD DM: Gelonin ana-logs with engineered cysteine residues form antibody immunoconjugates with unique properties. J. Biol Chem. (1994) 269 13:9644–9650.
   PubMed Web of Science ®Google Scholar
• FISHWILD DM, WU HM, LIN K, CARROLL SF, BERNHARD SI: Gelonin anti-T cell immunoconjugates are more cy-totoxic and are internalized differently compared to RTA immunoconjugates. FASEB J (1994) 8:4–5.
   Google Scholar
• SCOTT CF, GOLDMACHER VS, LAMBERT JM, CHARI R, BLATTER W: The antileukemic efficacy of an immuno-toxin composed of a monoclonal antibody disulfide linked to the ribosome inactivating protein gelonin. Cancer Immunol. Immunother. (1987) 25:31–40.
   PubMed Web of Science ®Google Scholar
• TRAIL RA, WILLNER D, LASCH SJ et al.: Cure of xeno- grafted human carcinomas by BR96-doxorubicin con-jugates. Science (1993) 261:212–215.
   PubMed Web of Science ®Google Scholar
• •The first paper to show the efficacy of an immunoconjugate prepared with chimeric monoclonal antibodies.
   Google Scholar
• BAGSHAWE KD, SPRINGER CJ, SCHREIBER GJ et al.: A cy- totoxic agent can be generated selectively at cancer sites. Br. J. Cancer (1988) 58:700–703.
   PubMed Web of Science ®Google Scholar
• BLAKEY DC, BURKE PJ, DAVIES DH et al.: ZD2767 an im-proved system for antibody directed enzyme prodrug therapy that results in tumour regression in colorectal xenografts. Cancer Res. (1996) 56:3287–3292.
   PubMed Web of Science ®Google Scholar
• SHERWOOD RF: Advanced drug delivery reviews: en-zyme prodrug therapy. Adv. Drug Deily. Rev. (1996) 22:269–288.
   Web of Science ®Google Scholar
• •A detailed commentary on the use of enzyme pro-drug ther-apy in cancer.
   Google Scholar
• NICULESCU-DUVAZ I, SPRINGER CJ: Antibody directed enzyme prodrug therapy (ADEPT): a targeting strategy in cancer chemotherapy. Curr. Med. Chem. (1995) 2:687–706.
   Web of Science ®Google Scholar
• WILLMOTT N, CUMMINGS J, STUART JFB, FLORENCE AT: Adriamycin loaded albumin microspheres: prepara-tion, in vivo distribution and release in rat. Biopharm. Drug Dispos. (1985) 6:91–104.
   PubMed Web of Science ®Google Scholar
• GOLUMBEK PT, AZHARI R, JAFFEE EM et al.: Controlled release, biodegradable cytokine depots: a new ap-proach in cancer vaccine design. Cancer Res. (1993) 53:5841–5844.
   PubMed Web of Science ®Google Scholar
• OKADA H, YAMAMOTO M, HEYA T et al.: Drug delivery using biodegradable microspheres. J. Contd. Ref (1994) 28:121–129.
   Web of Science ®Google Scholar
• •A mechanism by which a water soluble anticancer peptide is encapsulated in PLGA microspheres is described.
   Google Scholar
• MATHIOWITZ E, JACOB JS, JONG YS et al: Biologically erodable microspheres as potential oral drug delivery systems. Nature (1997) 386:410–414.
   PubMed Web of Science ®Google Scholar
• ••The first report of the oral adminstration of bioadhesive mi-crospheres for gene therapy.
   Google Scholar
• JEYANTHI R, PANDURANGA RAO K: Preparation of gela-tin microspheres of bleomycin. Intern. J. Pharm. (1987) 35:177–179.
   Web of Science ®Google Scholar
• TSUNG M, BURGESS DJ: Preparation and stabilization ofheparin/gelatin complex coacervate microcapsules. J. Pharm. Sci. (1997) 86:603–607.
   PubMed Web of Science ®Google Scholar
• TSAI DC, HOWARD SA, HOGAN TF, MALANGA CJ, KANDZARI SJ: Preparation and in vitro evaluation of polylactic acid-mitomycin C microcapsules. J. Microen-cap. (1986) 3:181–183.
   PubMedGoogle Scholar
• JALIL R: Biodegradable poly (lactic) and poly (larticle co-glycolide) polymers in sustained drug delivery. Drug Dev. Ind. Pharm. (1990) 16:2353–2367.
   Web of Science ®Google Scholar
• POPA MI, AELENI N, IONESCU G: Preparation of 2,3 di-carboxycellulose microspheres containing antitu-mour agent as a drug carrier. Cellulose Chem. Tech. (1996) 30:33–38.
   Web of Science ®Google Scholar
• WIDDER KJ, SENYEI AE, SCARPELLI DG: Magnetic micro-spheres: a model system for site specific drug delivery in vivo. Proc. Soc. Exp. Biol. Med. (1978) 158:141–151.
   PubMed Web of Science ®Google Scholar
• GUPTA PK, HUNG CT Effect of carrier dose on the mul- tiple tissue disposition of doxorubicin hydrochloride administered via magnetic albumin microspheres in rats. J. Pharm. Sci. (1989) 78:745–748
   PubMed Web of Science ®Google Scholar
• TAKENAGA M: Application of lipid microspheres forthe treatment of cancer. Adv. Drug Delhi. Rev. (1996) 20:209–219.
   Web of Science ®Google Scholar
• WANG YM, SATO H, ADACHI I, HORIKOSHI I: Prepara-tion and characterization of poly (lactic-co-glycolic acid) microspheres for targeted delivery of a novel anticancer agent, taxol. Chem. Pharm. Bull. (1996) 44:1935–1940.
   PubMed Web of Science ®Google Scholar
• CHEN L, APTE RN, COHEN S: Characterization of PLGAmicrospheres for the controlled delivery of 11-10 for tumour immunotherapy. J. Contd. Ref (1997) 43:261–272.
   Web of Science ®Google Scholar
• CLELAND JL, JONES AJS: Stable formulations of recom-binant human growth hormone and interferon-gamma for microencapsulation in biodegradable mi-crospheres. Pharm. Res. (1996) 13:1464–1475.
   PubMed Web of Science ®Google Scholar
• BERCZI A, RITHNER M, SZUTS V, FRITZER M et al.: Influ-ence of conjugation of doxorubicin to transferrin on the iron uptake by K562 cells via receptor-mediated endocytosis. Eur. j Biochem. (1993) 213:427–436.
   PubMedGoogle Scholar
• SIZENSKY M, BARABAS K, FAULK WP: Characterization of the anti-cancer activity of transferrin-adriamycin conjugates. Am. J. Reprod. Immunol (1992) 27:163–166.
   PubMed Web of Science ®Google Scholar
• FRITZER M, BARABAS K, SZUTS V, BERCZI A et al: Cyto-toxicity of a tranferrin-adriamycin conjugate to anthracycline-resistant cells. Int. J. Cancer (1992) 52:619–623.
   PubMed Web of Science ®Google Scholar
• YAZDI PT, MURPHY RM: Quantitative analysis of pro-tein synthesis inhibition by transferrin toxin conju-gates. Cancer Res. (1994) 54:6387–6394.
   PubMed Web of Science ®Google Scholar
• LEMIEUX M, PAGE M: Sensitivity of multidrug-resistant MCF-7 cells to a transferrin-doxorubicin conjugate. Anticancer Res. (1994) 14:397–403.
   PubMed Web of Science ®Google Scholar
• SINGH M, ATWAL H, MICETICH R: Potency of Trf-adriamycin conjugate against human tumours in vivo. Anti Cancer Research (1998). (In Press.)
   Google Scholar
• RUTHNER M, BERCZI A, GOLDENBERGH: Interaction ofa doxorubicin-transferrin conjugate with isolated transferrin receptors. Life Sci. (1994) 54: 35–40.
   PubMed Web of Science ®Google Scholar
• COTTON M, LANGLE-ROUAULT F, KIRLAPPOS H et al.:Transferrin: polycation mediated introduction of DNA into leukemic cells. Proc. Natl. Acad. Sci. USA (1990) 87:4033–4037.
   PubMed Web of Science ®Google Scholar
• ZATLOUKAL K, SCHMIDT W, COTTON M et al.: Somaticgene therapy for cancer: the utility of transferrinfec-tion in generating tumour vaccines. Gene (1993) 135:199–207.
   PubMed Web of Science ®Google Scholar
• JOUBERT D, ARIATTI M et al. Further studies on tar- geted DNA transfer to cells using a highly efficient de-livery system of biotinylated transferrin and biotinylated polylysine complexed to streptavidin. J. Drug Target (1995) 2:509–515.
   PubMed Web of Science ®Google Scholar
• CHEN J, GARMOUS S, TAKAYANAGI et al: A novel gene delivery system using EGF receptor mediated endocy-tosis. FEBS Lett. (1994) 338:167–169.
   PubMed Web of Science ®Google Scholar
• KLAUBER N, PARANGI S, FLYNN E, HAMEL E, D'AMATO R J: Inhhibition of angiogensis and breast cancer in mice by the microtubule inhibtors 2-methoxyestradiol and taxol. Cancer Res. (1997) 57:81–86.
   PubMed Web of Science ®Google Scholar
• ROBERTSON ES, OOKA T, KIEFF ED: Epstein virus vec-tors for gene delivery to B Lymphocytes. Proc. Natl. Acad. ScL USA (1996) 93:11334–11340.
   PubMed Web of Science ®Google Scholar
• VIOLA JJ, MARTUZA RL: Gene therapies for glioblas-tomas. Bailleire's Gun. Neurol. (1996) 5(2):423–424.
   Google Scholar
• ••A novel way to treat brain tumours with gene therapy.
   Google Scholar
• FALLAUX FJ, BOUT A, VANDER V, WOLLENBER DJM et al: Per. C6 cells allow production of RCA free batches El deleted recombinant adenoviral vectors. Am. Soc. Gene Ther. (1998) 130:520.
   Google Scholar
• GYM WU, WILSON JM, SHALABY F et al.: Receptor medi-ated gene delivery in vivo: partial correction of genetic analbuminenia in nalgase rats. J. Biol. Chem. (1991) 266:14338–14342.
   PubMed Web of Science ®Google Scholar
• FENDER P, RUIGROK RWH, GOUT E et al.: Adenovirus dodechedron, a new vector for human gene transfer. Nature Biotech. (1997) 15:52–56.
   PubMed Web of Science ®Google Scholar
• MINWANG YA, SATO H, ADACHI I, HORIKOSHI: Optimi-zation of the formulation design of chitosan micro-spheres containing cisplatin. J. Pharm. Sci. (1996) 85:1204–1210.
   PubMed Web of Science ®Google Scholar
• CURLEY SA, ABRAMSON N, BENSON AB et al: Phase I study of intratumoral intradose-CDDP in patients with primary and metastatic liver tumours. Hepatology (1994) 20:279 A.
   Google Scholar
• Status of ATRIDOX and ATRIGEL. Company Communica-tion (May 22, 1997).
   Google Scholar
• NICHOLAS D, ROBERT M, LOREN M et al: Inhibition of growth of human tumor cell lines in nude mice by an antisense oligonucleotide inhibitor of protein kinase C-alpha expression. Cancer Res. (1996) 56:3499–3507.
   PubMed Web of Science ®Google Scholar
• HENRY SP, MONTEITH D, LEVIN AA: Antisense oligonu-cleotide inhibitors for the treatment of cancer. II. Toxi-cological properties of phosphorothioate oligodeoxynuceotides. Anti-Cancer Drug Des. (1997) 12:395–408.
   PubMedGoogle Scholar
• ARCHER GE, SAMPSON JH, MCLENDON RE et al: Treat-ment of neoplastic meningitis with intrathecal spartaject-busulfan. Proc. Am. Assoc. Cancer Res. (1996) 37:298–308.
   Google Scholar
• LIVERSIDGE M, SARPOTDAR P, HAJJ S et al.: Formulationand antitumor activity evaluation of nanocrystalline suspensions of poorly soluble anticancer drugs. Pharm. Res. (1996) 13:272–280.
   PubMed Web of Science ®Google Scholar
• MESCHER MF, ROGERS JD: Immunotherapy of estab-lished murine tumors with large multivalent immuno-gen and cyclophosphamide. j Immunother. With Emph. Tum. Immunol. (1996) 19:102–112.
   PubMed Web of Science ®Google Scholar
• MESCHER MF, SAVELIEV AE: Stimulation of tumor spe-cific immunity using tumor cell plasma membrane an-tigen. Methods Enzymol (1997) 12:155–164.
   Web of Science ®Google Scholar
• ZHANG L, NAZDAN A, HEYMAN RA et al.: Discovery of novel retinoic acid receptor agonists having potent antiproliferative activity in cervical cancer cells. J. Med. Chem. (1996) 39:2569–2663.
   Google Scholar
• SCHOONJANS K, KOSYKH V, DALLONGEVILLE J et al.: Re-tinoids increase human apolipoprotein A-11 expres-sion through activation of the retinoid X receptor but not the retinoic acid receptor. Mol. Cell Biol. (1996) 16:3350–3360.
   PubMed Web of Science ®Google Scholar
• CHEN SY, ZANI C, KHOURI Y, MARACSO WA: Design of a genetic immunotoxin to eliminate toxin immunogen-icity. Gene Ther. (1995) 2:116–123.
   PubMed Web of Science ®Google Scholar